CRL vs EBS · rev $4.05B vs rev $1.04B
Charles River Laboratories (CRL) versus Emergent Biosolutions Inc (EBS) — a side-by-side from cached financials, not a winner call.
Charles River Laboratories (CRL) is a diagnostics & research company listed on US.
Emergent Biosolutions Inc (EBS) is a drug manufacturers - specialty & generic company listed on US.
Latest reported CRL revenue for 2024-12-28 was $4.05B. Net income was $25.3M. Revenue was down 1.9% from 2023-12-30 to 2024-12-28. CRL currently screens at market cap $7.78B.
Latest reported EBS revenue for 2024-12-31 was $1.04B. Net income was -$190.6M. Revenue was down 0.5% from 2023-12-31 to 2024-12-31. EBS currently screens at market cap $416.4M.
CRL currently screens at market cap $7.78B. EBS currently screens at market cap $416.4M.
Not investment advice. Open the CRL and EBS stock pages for the full models.
Not investment advice.